Cardiovascular Biomarkers in Chronic Kidney Disease

Journal of Renal Nutrition

Volumn 22, Issue 1, 2012, Pages 120-127

  Park, Sun Hee ^a,b   Stenvinkel, Peter ^a   Lindholm, Bengt ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Kyungpook National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23;

ARTICLE; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; HUMAN; INFLAMMATION; PROGNOSIS; RENAL REPLACEMENT THERAPY; RISK FACTOR; UREMIA;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CYTOKINES; FIBROBLAST GROWTH FACTORS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RENAL DIALYSIS; RISK FACTORS; UREMIA; VASCULAR CALCIFICATION;

EID: 84855171323     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2011.10.021     Document Type: Article

References (65)

1. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
2. Hallan S.I., Dahl K., Oien C.M., et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ 2006, 333:1047.
3. Khot U.N., Khot M.B., Bajzer C.T., et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290:898-904.
4. Shah T., Casas J.P., Cooper J.A., et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 2009, 38:217-231.
5. Blankenberg S., Zeller T., Saarela O., et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 2010, 121:2388-2397.
6. Matsushita K., van der Velde M., et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375:2073-2081.
7. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):S1-S266. National Kidney Foundation.
8. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
9. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
10. Stenvinkel P., Carrero J.J., Axelsson J., Lindholm B., Heimburger O., Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. Clin J Am Soc Nephrol 2008, 3:505-521.
11. U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United State. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD, 2009.
12. Snyder J.J., Collins A.J. KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the United States CKD population: National Health and Nutrition Examination Survey 1999-2004. Am J Nephrol 2009, 30:44-54.
13. Stenvinkel P, Herzog CA. Comprehensive clinical nephrology, 4th ed. Floege, Johnson, and Feehally. St. Louis, MO: Mosby.
14. Carrero J.J., Stenvinkel P. Inflammation in end-stage renal disease-what have we learned in 10 years?. Semin Dial 2010, 23:498-509.
15. Meuwese C.L., Halbesma N., Stenvinkel P., et al. Variations in C-reactive protein during a single haemodialysis session do not associate with mortality. Nephrol Dial Transplant 2010, 25:3717-3723.
16. Oldani S. Plasma Pentraxin-3 as a marker of bio-incompatibility in haemodialysis patients. J Nephrol. In press.
17. Zimmermann J., Herrlinger S., Pruy A., Metzger T., Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999, 55:648-658.
18. Bologa R.M., Levine D.M., Parker T.S., et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998, 32:107-114.
19. Reddan D.N., Klassen P.S., Szczech L.A., et al. White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant 2003, 18:1167-1173.
20. Zoccali C., Mallamaci F., Tripepi G., et al. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 2003, 254:132-139.
21. Stenvinkel P., Heimburger O., Wang T., Lindholm B., Bergstrom J., Elinder C.G. High serum hyaluronan indicates poor survival in renal replacement therapy. Am J Kidney Dis 1999, 34:1083-1088.
22. Kalantar-Zadeh K., Brennan M.L., Hazen S.L. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2006, 48:59-68.
23. Ulrich C., Heine G.H., Seibert E., Fliser D., Girndt M. Circulating monocyte subpopulations with high expression of angiotensin-converting enzyme predict mortality in patients with end-stage renal disease. Nephrol Dial Transplant 2010, 25:2265-2272.
24. Suliman M.E., Qureshi A.R., Carrero J.J., et al. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. QJM 2008, 101:397-405.
25. Stenvinkel P., Lindholm B. C-reactive protein in end-stage renal disease: are there reasons to measure it?. Blood Purif 2005, 23:72-78.
26. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
27. Koenig W., Lowel H., Baumert J., Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004, 109:1349-1353.
28. Panichi V., Rizza G.M., Paoletti S., et al. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant 2008, 23:2337-2343.
29. Panichi V., Taccola D., Rizza G.M., et al. Ceruloplasmin and acute phase protein levels are associated with cardiovascular disease in chronic dialysis patients. J Nephrol 2004, 17:715-720.
30. Pecoits-Filho R., Barany P., Lindholm B., Heimburger O., Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002, 17:1684-1688.
31. Honda H., Qureshi A.R., Heimburger O., et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006, 47:139-148.
32. Rao M., Guo D., Perianayagam M.C., et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2005, 45:324-333.
33. Panichi V., Maggiore U., Taccola D., et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004, 19:1154-1160.
34. Tripepi G., Mallamaci F., Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005, 16(Suppl 1):S83-S88.
35. Panichi V., Taccola D., Rizza G.M., et al. Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients. Nephron Clin Pract 2006, 102:c51-c58.
36. Tong M., Carrero J.J., Qureshi A.R., et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2007, 2:889-897.
37. Boehme M., Kaehne F., Kuehne A., et al. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. Nephrol Dial Transplant 2007, 22:2224-2229.
38. Hofmann Bowman M.A., Gawdzik J., Bukhari U., et al. S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc Biol 2011, 31:337-344.
39. Nakashima A., Carrero J.J., Qureshi A.R., et al. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2010, 5:2213-2219.
40. Blacher J., Guerin A.P., Pannier B., Marchais S.J., London G.M. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001, 38:938-942.
41. Moester M.J., Papapoulos S.E., Lowik C.W., van Bezooijen R.L. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 2010, 87:99-107.
42. Kastrup J., Johansen J.S., Winkel P., et al. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 2009, 30:1066-1072.
43. Stenvinkel P., Wang K., Qureshi A.R., et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005, 67:2383-2392.
44. Wang A.Y., Woo J., Lam C.W., et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005, 20:1676-1685.
45. Jono S., Ikari Y., Vermeer C., et al. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 2004, 91:790-794.
46. Schlieper G., Westenfeld R., Kruger T., et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol 2011, 22:387-395.
47. Kazama J.J., Shigematsu T., Yano K., et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002, 39:525-532.
48. Nitta K., Akiba T., Uchida K., et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003, 42:303-309.
49. Morena M., Terrier N., Jaussent I., et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006, 17:262-270.
50. Matsubara K., Stenvinkel P., Qureshi A.R., et al. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. J Nephrol 2009, 22:774-782.
51. Morony S., Tintut Y., Zhang Z., et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008, 117:411-420.
52. Mirza M.A., Larsson A., Lind L., Larsson T.E. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009, 205:385-390.
53. Seiler S., Reichart B., Roth D., Seibert E., Fliser D., Heine G.H. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010, 25:3983-3989.
54. Jean G., Terrat J.C., Vanel T., et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009, 24:2792-2796.
55. Olauson H., Qureshi A.R., Miyamoto T., et al. Relation between serum fibroblast growth factor-23 level and mortality inincident dialysis patients: are gender and cardiovascular disease confounding the relationship?. Nephrol Dial Transplant 2010, 25:3033-3038.
56. Wang A.Y., Lam C.W., Wang M., et al. Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients. Nephrol Dial Transplant 2009, 24:1962-1969.
57. Meuwese C.L., Snaedal S., Halbesma N., et al. Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-alpha are similarly associated with survival in haemodialysis patients. Nephrol Dial Transplant 2011, 26:1313-1318.
58. Sandhu S., Har B.J., Aggarwal S.G., Kavanagh K.M., Ramadan D., Exner D.V. Predictive value of repeated versus single N-terminal pro B-type natriuretic peptide measurements early after-myocardial infarction. Pacing Clin Electrophysiol 2009, 32(Suppl 1):S86-S89.
59. Roberts M.A., Hare D.L., Macmillan N., Ratnaike S., Sikaris K., Ierino F.L. Serial increased cardiac troponin T predicts mortality in asymptomatic patients treated with chronic haemodialysis. Ann Clin Biochem 2009, 46(Pt 4):291-295.
60. Enia G., Panuccio V., Cutrupi S., et al. Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2007, 22:538-544.
61. Carrero J.J., Qureshi A.R., Axelsson J., et al. Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Intern Med 2007, 262:690-701.
62. Zethelius B., Berglund L., Sundstrom J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358:2107-2116.
63. Mallamaci F., Tripepi G., Cutrupi S., Malatino L.S., Zoccali C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005, 67:2330-2337.
64. Cohen L.M., Ruthazer R., Moss A.H., Germain M.J. Predicting six-month mortality for patients who are on maintenance hemodialysis. Clin J Am Soc Nephrol 2010, 5:72-79.
65. Moss A.H., Ganjoo J., Sharma S., et al. Utility of the " surprise" question to identify dialysis patients with high mortality. Clin J Am Soc Nephrol 2008, 3:1379-1384.